Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.17 - $1.92 $9,392 - $15,413
-8,028 Reduced 68.72%
3,654 $5,000
Q4 2023

Feb 13, 2024

SELL
$0.6 - $1.31 $9,729 - $21,242
-16,216 Reduced 58.13%
11,682 $10,000
Q3 2023

Nov 14, 2023

BUY
$1.05 - $3.37 $25,042 - $80,374
23,850 Added 589.18%
27,898 $29,000
Q2 2023

Aug 14, 2023

SELL
$2.44 - $4.53 $1,764 - $3,275
-723 Reduced 15.15%
4,048 $10,000
Q1 2023

May 09, 2023

BUY
$3.72 - $5.4 $6,394 - $9,282
1,719 Added 56.32%
4,771 $19,000
Q4 2022

Feb 10, 2023

SELL
$3.41 - $12.93 $8,941 - $33,902
-2,622 Reduced 46.21%
3,052 $16,000
Q3 2022

Nov 10, 2022

BUY
$12.59 - $17.67 $43,322 - $60,802
3,441 Added 154.1%
5,674 $74,000
Q2 2022

Aug 15, 2022

BUY
$10.58 - $17.5 $12,886 - $21,315
1,218 Added 120.0%
2,233 $29,000
Q1 2022

May 12, 2022

BUY
$13.81 - $18.6 $3,852 - $5,189
279 Added 37.91%
1,015 $16,000
Q4 2021

Feb 14, 2022

SELL
$17.26 - $22.02 $94,912 - $121,087
-5,499 Reduced 88.2%
736 $13,000
Q3 2021

Nov 15, 2021

BUY
$20.15 - $26.19 $69,356 - $90,145
3,442 Added 123.24%
6,235 $131,000
Q2 2021

Aug 16, 2021

BUY
$15.06 - $30.03 $16,430 - $32,762
1,091 Added 64.1%
2,793 $55,000
Q1 2021

May 17, 2021

BUY
$24.99 - $31.93 $11,620 - $14,847
465 Added 37.59%
1,702 $49,000
Q4 2020

Feb 16, 2021

SELL
$16.21 - $31.44 $80,288 - $155,722
-4,953 Reduced 80.02%
1,237 $37,000
Q3 2020

Nov 16, 2020

BUY
$15.59 - $19.97 $35,482 - $45,451
2,276 Added 58.15%
6,190 $98,000
Q2 2020

Aug 13, 2020

BUY
$11.97 - $23.47 $31,002 - $60,787
2,590 Added 195.62%
3,914 $77,000
Q1 2020

May 15, 2020

BUY
$10.0 - $19.51 $13,240 - $25,831
1,324 New
1,324 $16,000
Q3 2019

Nov 05, 2019

SELL
$13.09 - $18.19 $14,032 - $19,499
-1,072 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$12.56 - $16.6 $13,464 - $17,795
1,072 New
1,072 $16,000

Others Institutions Holding NGM

About NGM BIOPHARMACEUTICALS INC


  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.